Phase 1 Study of SBS-147 in Healthy Adults

This study is part of the HEAL Initiative supported by the NIH. The purpose of this study is to learn how safe the study drug, SBS-147, is and how people's bodies respond to and process it. Researchers will also look for any side effects that may occur when taking SBS-147. Some participants will receive SBS-147, and others will receive a placebo, which looks the same but does not contain any medicine. This helps researchers fairly compare results. The study includes two parts: Single-Dose Group, where Participants receive SBS-147 or placebo one time. Multiple-Dose Group, where Participants receive SBS-147 or placebo once or twice daily for 7 days.

NCT Number	NCT07335913
Lead Sponsor	Sparian Biosciences, Inc Collaborators: National Institutes of Health (NIH), Altasciences Company Inc.
Conditions	Pain Acute, Pain
Enrollment	80 participants
Start Date	2026-01-08
Primary Completion	2027-01-31 (estimated)
Study Completion	2027-02-28 (estimated)
Updated on ClinicalTrials.gov	2026-03-03